3 Healthcare Stocks in Focus; AMGN, BIIB, AFFY

Amgen Inc. ( NASDAQ: AMGN ), on Monday, announced its fourth-quarter financial
results. The company reported fourth-quarter adjusted earnings per share of
$1.17, up 11% over the same period in 2009. For full year 2010, the company
reported adjusted earnings per share of $5.21, up 6%. Amgen also announced that
for 2011 it expects the total revenue to be in the range of $15.1-$15.5 billion
and adjusted EPS to be in the range of $5.00-$5.20. Amgen shares have a 52-week
range of $50.26-$61.26. In the last one year, the stock gained 3.345%. Thousand
Oaks, California-based Amgen is an independent biotechnology medicines company,
engaged in the discovery, development, manufacturing and marketing of medicines
for grievous illnesses. Biogen Idec Inc. ( NASDAQ: BIIB ), last week, announced
the issuance of negative opinion recommending against approval of its FAMPYRA by
the European Medicines Agencys (EMA) Committee for Medicinal Products for Human
Use (CHMP). Biogen said that it plans to appeal this opinion and request a
re-examination of the decision by the CHMP. Biogen shares have a 52-week range
of $45.96-$68.99. The stock gained 26.47% in the last one year. Cambridge,
Massachusetts-based Biogen is a biotechnology company. The company's products
include AVONEX, RITUXAN, TYSABRI and FUMADERM. Affymax Inc. ( NASDAQ: AFFY ),
earlier this month, announced the appointment of John Orwin as its new CEO and
member of Board of Directors, effective February 1, 2011. Orwin will replace
Arlene Morris as the company's CEO. Affymax shares have a 52-week range of
$4.90-$26.20. The stock fell 66.98% in the last one year. Affymax is a
biopharmaceutical company based in Palo Alto, California and engaged in the
development of drugs to improve the treatment of serious and often
life-threatening conditions. This corporate profile is provided for information
purposes only and should not be used as the basis for any investment decision.
We are neither licensed nor qualified to provide investment advice. We were not
paid, nor do we hold a position in these stocks. We reserve the right to buy or
sell any stock mentioned in this report at any time after this post.